Plaque, Amyloid

The grounding supports amyloid plaque formation as a consequence of abnormal amyloid beta (Aβ) production and aggregation, especially from processing of amyloid beta-protein precursor (APP) by β-secretase and γ-secretase. The literature also notes that a small number of familial Alzheimer cases are driven by genetic mutations, including associations with presenilin-1 and apolipoprotein E variants.

Amyloid plaques are composed mainly of aggregated amyloid beta peptides that accumulate extracellularly, particularly in the brain. The reviewed literature describes plaque build-up as occurring early in Alzheimer disease, before cognitive deficits, and as part of a mixed proteinopathy that also involves tau pathology, synaptic loss, and glial responses.

The supplied grounding supports genetic risk in familial cases and associations with apolipoprotein E, including ApoE4, as well as presenilin-1-related disease. Aging is also repeatedly linked to the broader neuropathologic context in which amyloid plaque burden is studied.

The grounding does not support a standard treatment for amyloid plaque as a standalone entity. In the Alzheimer disease literature, amyloid beta has been a major therapeutic target, with anti-amyloid beta therapies and other amyloid-targeted approaches discussed at the drug-class level.